Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan long-term extension add-on study in paroxysmal nocturnal hemoglobinuria
2021-004253-22Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events and serious treatment-emergent adverse events. Started May 2022; status: active.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2021-004253-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004253-22.